TYME Announces $100 Million Registered Direct Offering of Common Stock Priced At-the-Market under Nasdaq Rules

BEDMINSTER, N.J.--(BUSINESS WIRE)--Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTsTM), today announced that it has entered into definitive agreements with several healthcare-focused institutional and other institutional investors for the sale of an aggregate of 40,000,000 shares of its common stock at a purchase price of $2.50 per share in a registered direct offering priced at-the-market under Nasdaq Rules. The offering is expected to close on or about February 8, 2021, subject to the satisfaction of customary closing conditions.